Generated by AI
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing peptide-based therapies for obesity, metabolic disorders, and serious liver diseases. The company’s lead product candidate, pemvidutide, is a dual GLP-1 and glucagon receptor agonist being studied for conditions such as metabolic dysfunction-associated steatohepatitis, alcohol use disorder, alcohol-associated liver disease, and obesity. Altimmune is also developing HepTcell, an immunotherapeutic program designed for chronic hepatitis B. Through these programs, Altimmune operates at the intersection of metabolic medicine, hepatology, and immunotherapy, with a pipeline aimed at addressing complex diseases that currently have limited treatment options. The company is headquartered in Gaithersburg, Maryland.
Website910 Clopper Road
Gaithersburg, MD, 20878
United States
The latest articles about ALT.
2026-11-14. The following slide deck was published by Altimmune, Inc.
Altimmune remains a Sell as pemvidutide lacks clear differentiation in the competitive MASH landscape. Read more on ALT stock here.
Summary of Nov 19's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Investors talking about ALT also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.